James E. Flynn - 15 Jul 2024 Form 4 Insider Report for BiomX Inc. (PHGE)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Jul 2024, 18:09:45 UTC
Prior SEC filing
15 Jul 2024
Next SEC filing
12 Sep 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan Isler, Attorney-in-Fact

Key filing fact

James E. Flynn filed Form 4 for BiomX Inc. (PHGE) on 17 Jul 2024.

Key facts

  • This page summarizes James E. Flynn's Form 4 filing for BiomX Inc. (PHGE).
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 17 Jul 2024, 18:09.

Change

  • Previous filing in this sequence was filed on 15 Jul 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHGE transaction

Common Stock

Options Exercise

Transaction value
Shares
+5,883,000
Change %
+193%
Price
Shares after
8,938,049
Date
15 Jul 2024
Ownership
Through Deerfield Private Design Fund V, L.P.
Footnotes
F1, F2, F3
PHGE transaction

Common Stock

Options Exercise

Transaction value
Shares
+5,883,000
Change %
+193%
Price
Shares after
8,938,049
Date
15 Jul 2024
Ownership
Through Deerfield Healthcare Innovations Fund II, L.P.
Footnotes
F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PHGE transaction Derivative

Series X Non-Voting Convertible Preferred Stock

Options Exercise

Transaction value
Shares
-5,883
Change %
-11%
Price
Shares after
47,957
Date
15 Jul 2024
Ownership
Through Deerfield Private Design Fund V, L.P.
Underlying class
Common Stock
Underlying amount
5,883,000
Exercise price
Footnotes
F1, F2, F3, F4
PHGE transaction Derivative

Series X Non-Voting Convertible Preferred Stock

Options Exercise

Transaction value
Shares
-5,883
Change %
-11%
Price
Shares after
47,957
Date
15 Jul 2024
Ownership
Through Deerfield Healthcare Innovations Fund II, L.P.
Underlying class
Common Stock
Underlying amount
5,883,000
Exercise price
Footnotes
F1, F2, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

In accordance with the Certificate of Designation of Preferences, Rights and Limitations (the "Certificate of Designation") governing the Series X Non-voting Convertible Preferred Stock ("Series X Preferred Stock"), on July 15, 2024, 5,883 shares of Series X Preferred Stock held by each of Deerfield Private Design Fund V, L.P. ("Fund V") and Deerfield Healthcare Innovations Fund II, L.P. ("HIF II" and, together with Fund V, the "Funds") automatically converted into 5,883,000 shares of Common Stock. The acquisition or deemed acquisition of such shares of Common Stock upon such conversion, and any disposition or deemed disposition of such shares of Series X Preferred Stock upon such conversion, were exempted pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

Footnote F2

This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt V, L.P. is the general partner of Fund V. Deerfield Mgmt HIF II, L.P. is the general partner of HIF II. Deerfield Management Company, L.P. is the investment manager of each Fund. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P. and Deerfield Management Company, L.P.

Footnote F3

In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Footnote F4

Each share of Series X Preferred Stock is convertible at any time at the election of the holder, subject to a beneficial ownership limitation, into 1,000 shares of Common Stock (subject to adjustment) in accordance with the Certificate of Designation. The Series X Preferred Stock has no expiration date.

SEC remarks

Jonathan S. Leff, a partner in Deerfield Management, serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 18, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .